Hui-Ling Zhu HAN JIANDE. Clinical analysis of 30 cases of cutaneous adverse reactions to tyrosine kinase inhibitors[J]. Chinese Journal of Dermatology, 2018, 51(2): 101-105.doi:10.3760/cma.j.issn.0412-4030.2018.02.004
Fiala O, Pesek M, Finek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice[J]. Neoplasma, 2013,60(1):26⁃32. doi: 10.4149/neo_2013_004.<br />
[2]
Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in non⁃small cell lung cancer patients: results of an Experts Panel Meeting[J]. Crit Rev Oncol Hematol, 2008,66(2):155⁃162. doi: 10.1016/j.critrevonc.2007. 10.004.<br />
[3]
Common Terminology Criteria for Adverse Events [CTCAE]v4.0. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute[OL]. May 28, 2009.Available from: URL:http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010⁃06⁃14_QuickReference_5x7.pdf.<br />
[4]
Johnston JB, Navaratnam S, Pitz MW, et al. Targeting the EGFR pathway for cancer therapy[J]. Curr Med Chem, 2006,13(29):3483⁃3492.<br />
[5]
Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies. Part I: Inhibitors of the cellular membrane[J]. J Am Acad Dermatol, 2015,72(2):203⁃218; quiz 219⁃220. doi: 10.1016/j.jaad.2014.07.032.<br />
[6]
Reyes⁃Habito CM, Roh EK. Cutaneous reactions to chemothera⁃peutic drugs and targeted therapy for cancer: Part II. Targeted therapy[J]. J Am Acad Dermatol, 2014,71(2):217.e1⁃217.e11; quiz 227⁃228. doi: 10.1016/j.jaad.2014.04.013.<br />
[7]
Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi⁃target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016,9(1):105. doi: 10.1186/s13045⁃016⁃0332⁃8.<br />
[8]
Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors[J]. Mol Cell Oncol, 2015,2(4):e1004969. doi: 10.1080/23723556.2015.1004969.<br />
[9]
Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors[J]. Ann Oncol, 2005,16(9):1425⁃1433. doi: 10.1093/annonc/mdi279.<br />
[10]
Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor⁃associated dermatologic toxicities[J]. Support Care Cancer, 2011,19(8):1079⁃1095. doi: 10.1007/s00520⁃011⁃1197⁃6.<br />
[11]
Abdullah SE, Haigentz M, Piperdi B. Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management[J]. Chemother Res Pract, 2012,2012: 351210. doi: 10.1155/2012/351210.<br />
[12]
Štulhofer BD, Martinac I, Ledic DD, et al. Adverse reaction to cetuximab, an epidermal growth factor receptor inhibitor[J]. Acta Dermatovenerol Croat, 2016,24(1):70⁃72.<br />